Congenital Amegakaryocytic Thrombocytopenia: An Intrinsic Hematopoietic Stem Cell Defect

@article{Freedman1990CongenitalAT,
  title={Congenital Amegakaryocytic Thrombocytopenia: An Intrinsic Hematopoietic Stem Cell Defect},
  author={Melvin H. Freedman and Zeev E Estrov},
  journal={Journal of Pediatric Hematology/Oncology},
  year={1990},
  volume={12},
  pages={225–230}
}
Serial studies of bone marrow (BM) hematopoiesis using clonogenic assays were performed in an infant with congenital amegakaryocytic thrombocytopenia. Initially, when the only hematological abnormality was isolated thrombocytopenia, the number of clonogenic BM hematopoietic progenitors was comparable to controls, including the number of megakaryocyte precursors. As the disease evolved into aplastic anemia over an 11-month period, the peripheral blood counts declined, and colony numbers from… 

Effect of stem cell factor on in vitro erythropoiesis in patients with bone marrow failure syndromes.

Improved in vitro erythropoiesis with SCF in all types of inherited marrow failure syndromes does not suggest a common defect involving kit or SCF, but implies that SCF may be helpful in the treatment of hematopoietic defects of varied etiologies.

Haematopoietic stem cell transplantation for amegakaryocytic thrombocytopenia

Both patients with matched unrelated donor transplants died, six patients are well with stable platelet counts 3–27 months after transplantation, and the benefit of using alternative marrow donors should be carefully evaluated.

Engraftment of unrelated donor stem cells in children with familial amegakaryocytic thrombocytopenia

The difficulty in achieving engraftment of unrelated donor stem cells in two children with familial amegakaryocytic thrombocytopenia suggests that in future cases additional measures may be necessary, for example, a more aggressive preparative regimen or an increased stem cell dose.

Gene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia.

To avoid adverse reactions, improved retroviral vectors were designed that mediate reduced and more physiological Mpl expression that expressed Mpl from the phosphoglycerate kinase (PGK) or the murine Mpl promoter.

Thrombopoietin Is Essential for the Maintenance of Normal Hematopoiesis in Humans

Like CAMT patients, mice lacking the TPO receptor c‐Mpl demonstrate a major reduction of early hematopoietic progenitor cells of all lineages, however, these mice achieve a normal marrow cellularity and composition, despite the lack of megakaryocytes.

Defective response to thrombopoietin and impaired expression of c‐mpl mRNA of bone marrow cells in congenital amegakaryocytic thrombocytopenia

The results of this study suggest that the pathophysiology in CAMT may be a defective response to TPO in haemopoietic cells through impaired expression of c‐mpl mRNA.

Congenital amegakaryocytic thrombocytopenia: The diagnostic importance of combining pathology with molecular genetics

The presence of a normal number of megakaryocytes on an initial bone marrow aspirate should not exclude CAMT from the differential diagnosis of thrombocytopenia within the first year of life.

Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients

Two groups of patients were defined according to the course of platelet counts during the first year of life, which also differed in the Course of development of pancytopenia, and fifteen patients were treated with haematopoietic stem cell transplantation, four of whom died of transplantation‐related events.

Advances in the understanding of congenital amegakaryocytic thrombocytopenia

Congenital amegakaryocytic thrombocytopenia (MIM #604498) is an extremely rare inherited bone marrow failure syndrome, usually presenting as a severe thrombocytopenia at birth due to ineffective

c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia.

A defective c-Mpl expression due to c-mpl mutations is proposed as the cause for thrombocytopenia and progression into pancy topenia seen in patients with CAMT.